Last reviewed · How we verify
Androgen blockade + radiation therapy
Androgen blockade suppresses testosterone-driven prostate cancer cell growth, while radiation therapy delivers targeted cytotoxic damage to tumor cells.
Androgen blockade suppresses testosterone-driven prostate cancer cell growth, while radiation therapy delivers targeted cytotoxic damage to tumor cells. Used for Locally advanced prostate cancer, High-risk prostate cancer.
At a glance
| Generic name | Androgen blockade + radiation therapy |
|---|---|
| Sponsor | Université de Sherbrooke |
| Drug class | Androgen receptor antagonist + radiation therapy (combination) |
| Target | Androgen receptor (AR) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Androgen deprivation therapy (ADT) inhibits the androgen receptor signaling pathway that drives prostate cancer proliferation, rendering cancer cells more radiosensitive. Concurrent radiation therapy exploits this sensitized state to deliver localized high-dose ionizing radiation that causes DNA damage and cell death. The combination approach aims to improve local control and overall survival in prostate cancer patients.
Approved indications
- Locally advanced prostate cancer
- High-risk prostate cancer
Common side effects
- Erectile dysfunction
- Hot flashes
- Fatigue
- Bowel toxicity (diarrhea, proctitis)
- Urinary toxicity (dysuria, frequency)
- Gynecomastia
- Decreased libido
Key clinical trials
- Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer (PHASE1, PHASE2)
- Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC (PHASE3)
- Androgen-responsive POSLUMA-guided Intra-prostatic Boost (PHASE2)
- Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy (PHASE1, PHASE2)
- INTREPId (INTermediate Risk Erection PreservatIon Trial) (PHASE2)
- Study on the Role of Hormonal Treatment for Two Dosage Levels of Prostate Radiation Therapy Versus Prostate Radiation Therapy Alone (PHASE3)
- Duration of Androgen Blockade Combined With Pelvic Irradiation in Prostate Cancers (PHASE3)
- Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |